At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABOS Acumen Pharmaceuticals, Inc.
Market Closed 10-25 16:00:00 EDT
2.90
+0.16
+5.84%
盘后2.83
-0.07-2.41%
19:19 EDT
High3.03Low2.75Vol299.45K
Open2.75D1 Closing2.74Amplitude10.22%
Mkt Cap174.23MTradable Cap94.01MTotal Shares60.08M
T/O870.55KT/O Rate0.92%Tradable Shares32.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Acumen Pharmaceuticals To Deliver Late-Breaking Presentation At 17Th Annual Clinical Trials On Alzheimer’S Disease (Ctad) Conference
Reuters  ·  10-23 22:30
BRIEF-Acumen Pharmaceuticals To Deliver Late-Breaking Presentation At 17Th Annual Clinical Trials On Alzheimer’S Disease (Ctad) Conference
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  10-23
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire  ·  10-23
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
3 US Penny Stocks With Market Caps Under $500M To Consider
Simply Wall St.  ·  10-22
3 US Penny Stocks With Market Caps Under $500M To Consider
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
TIPRANKS  ·  10-07
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
Stifel Nicolaus Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)
TIPRANKS  ·  10-04
Stifel Nicolaus Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-03
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Strong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193
TIPRANKS  ·  10-03
Strong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
GlobeNewswire  ·  10-01
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease
MT Newswires Live  ·  09-26
Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease
BRIEF-Acumen Pharmaceuticals Extends Collaboration With Lonza To Add Drug Product Manufacturing Of Sabirnetug For Early Alzheimer’S Disease
Reuters  ·  09-26
BRIEF-Acumen Pharmaceuticals Extends Collaboration With Lonza To Add Drug Product Manufacturing Of Sabirnetug For Early Alzheimer’S Disease
Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
THOMSON REUTERS  ·  09-26
Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals Inc - Lonza to Provide DP Manufacturing Services From Visp Site
THOMSON REUTERS  ·  09-26
Acumen Pharmaceuticals Inc - Lonza to Provide DP Manufacturing Services From Visp Site
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
GlobeNewswire  ·  09-26
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
GlobeNewswire  ·  09-26
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
GlobeNewswire  ·  09-04
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
UBS Lowers Price Target on Acumen Pharmaceuticals to $6 From $14, Maintains Buy Rating
MT Newswires Live  ·  08-15
UBS Lowers Price Target on Acumen Pharmaceuticals to $6 From $14, Maintains Buy Rating
Buy Rating Justified by Acumen Pharmaceuticals’ Innovative Alzheimer’s Drug and Promising Clinical Trials
TIPRANKS  ·  08-14
Buy Rating Justified by Acumen Pharmaceuticals’ Innovative Alzheimer’s Drug and Promising Clinical Trials
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-14
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong Financials
TIPRANKS  ·  08-14
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong Financials

Introduction

Company Name.
Acumen Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Issue price:
--